China's NMPA approves XACDURO, an antibiotic for hospital-acquired and ventilator-associated pneumonia, developed by Entasis Therapeutics Inc.
China's NMPA approves XACDURO, an antibiotic drug for treating hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China. Developed by Entasis Therapeutics Inc., affiliated with Innoviva, the treatment has also been approved in the US. NMPA approval is based on positive results from the ATTACK trial, a global Phase 3 registrational trial that demonstrated XACDURO's safety and efficacy.
May 20, 2024
4 Articles